Trial
NCT00244257
Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Idiopathic Thrombocytopenic Purpura
Intervention
GMA161
Why stopped
Study terminated due to low enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-09